Pharmacokinetic herb–drug interaction of Xuesaitong dispersible tablet and aspirin after oral administration in blood stasis model rats

Phytomedicine

Volumn 26, Issue , 2017, Pages 62-68

  Dai, Guoliang ^a   Jiang, Zhitao ^a   Bai, Yongtao ^a   Zhang, Qian ^a   Zhu, Lei ^a   Bai, Xiaohui ^b   Ju, Wenzheng ^a   Pan, Ronghua ^b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Chinese Traditional Medicine Hospital of Liyang City   (China)

Author keywords

Aspirin; Herb drug interaction; Pharmacokinetics; UHPLC MS MS; Xuesaitong dispersible tablet

Indexed keywords

ACETYLSALICYLIC ACID; GINSENOSIDE RD; GINSENOSIDE RG 1; NOTOGINSENOSIDE R1; PANAX NOTOGINSENG EXTRACT; UNCLASSIFIED DRUG; XUESAITONG; GINSENOSIDE; HERBACEOUS AGENT; SAPONIN; XUESETONG;

ANIMAL EXPERIMENT; ARTICLE; DISPERSIBLE TABLET; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; ELIMINATION RATE CONSTANT; HEMOSTASIS; HERB DRUG INTERACTION; MALE; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VOLUME OF DISTRIBUTION; ANIMAL; BLOOD VOLUME; DRUG EFFECTS; HOMEOSTASIS; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ASPIRIN; BLOOD VOLUME; DRUGS, CHINESE HERBAL; GINSENOSIDES; HERB-DRUG INTERACTIONS; HOMEOSTASIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SAPONINS;

EID: 85011926907     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2017.01.010     Document Type: Article

References (25)

1. Chhonker, Y.S., Pandey, C.P., Chandasana, H., Laxman, T.S., Prasad, Y.D., Narain, V.S., Dikshit, M., Bhatta, R.S., Simultaneous quantitation of acetylsalicylic acid and clopidogrel along with their metabolites in human plasma using liquid chromatography tandem mass spectrometry. Biomed. Chromatogr. 30 (2015), 466–473.
2. Chockalingam, A., Campbell, N.R., Fodor, J.G., Worldwide epidemic of hypertension. Can. J. Cardiol. 22 (2006), 553–555.
3. Ferguson, R.K., Boutros, A.R., Death following self-poisoning with aspirin. J. Am. Med. Assoc. 213 (1970), 1186–1188.
4. Gaziano, T.A., Bitton, A., Anand, S., Abrahams-Gessel, S., Murphy, A., Growing epidemic of coronary heart disease in low- and middle-income countries. Curr. Probl. Cardiol. 35 (2010), 72–115.
5. Gong, W., Xiao, Y., Zhang, M., Wang, Y., Wang, Y., Synergistic protective effects of salvianolic acids and Panax notoginseng saponins on cardiomyocytes with hypoxia-reoxygenation injury. China J. Chin. Mater. Med. 38 (2013), 1046–1051.
6. Han, M., Han, L.M., Wang, Q.S., Bai, Z.H., Fang, X.L., Mechanism of oral absorption of panax notoginseng saponins. Acta Pharm. Sin. 41 (2006), 498–505.
7. Hennekens, C.H., Bjorkman, D.J., Evolving concepts in the primary prevention of cardiovascular disease: aspirin then and now. Future Cardiol 10 (2014), 583–586.
8. Hunter, D.J., Reddy, K.S., Noncommunicable diseases. N. Engl. J. Med. 369 (2013), 1336–1343.
9. Huang, X.P., Ding, H., Wang, B., Qiu, Y.Y., Tang, Y.H., Zeng, R., Deng, C.Q., Effects of the main active components combinations of Astragalus and Panax notoginseng on energy metabolism in brain tissues after cerebral ischemia-reperfusion in mice. Pharm. Mag. 11 (2015), 732–739.
10. Kaufman, F.L., Dubansky, A.S., Darvon poisoning with delayed salicylism: a case report. Pediatrics 49 (1972), 610–611.
11. Levy, G., Tsuchiya, T., Salicylate accumulation kinetics in man. N. Engl. J. Med. 287 (1972), 430–432.
12. Li, H.X., Han, S.Y., Wang, X.W., Ma, X., Zhang, K., Wang, L., Ma, Z.Z., Tu, P.F., Effect of the carthamins yellow from Carthamus tinctorius L. on hemorheological disorders of blood stasis in rats. Food Chem. Toxicol. 47 (2009), 1797–1802.
13. Li, X.Y., Sun, J.G., Wang, G.J., Hao, H.P., Liang, Y., Zheng, Y.T., Yan, B., Sheng, L.S., Simultaneous determination of panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 in rat plasma by HPLC/ESI/MS: platform for the pharmacokinetic evaluation of total panax notoginsenoside, a typical kind of multiple constituent traditional Chinese medicine. Biomed. Chromatogr. 21 (2007), 735–746.
14. Liang, F., Hua, J.X., Absorption profiles of sanchinoside R1 and ginsenoside Rg1 in the rat intestine. Eur. J. Drug Metab. Pharmacokinet. 30 (2005), 261–268.
15. Lin, K., Chen, M.L., Clinical analysis on ozagrel sodium combined with aspirin and xuesaitong injection in treatment of 90 cases of progressive ischemic stroke. Pract. Prev. Med. 18 (2011), 1935–1936.
16. Liu, J., Wang, Y., Qiu, L., Yu, Y., Wang, C., Saponins of Panax notoginseng: chemistry, cellular targets and therapeutic opportunities in cardiovascular diseases. Expert Opin. Investig. Drugs 23 (2014), 523–539.
17. Liu, L., Zhu, L., Zou, Y., Liu, W., Zhang, X., Wei, X., Hu, B., Chen, J., Panax notoginseng saponins promotes stroke recovery by influencing expression of Nogo-A, NgR and p75NGF, in vitro and in vivo. Biol. Pharm. Bull. 37 (2014), 560–568.
18. Long, W., Zhang, S.C., Wen, L., Mu, L., Yang, F., Chen, G., In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration. J. Ethnopharmacol. 156 (2014), 199–208.
19. Shang, Q., Xu, H., Liu, Z., Chen, K., Liu, J., Oral panax notoginseng preparation for coronary heart disease: a systematic review of randomized controlled trials. Evid. Based Complement. Altern. Med., 2013, 2013, 940125.
20. U.S. Food and Drug administration, 2013. http://www.fda.gov/Drugs/GuidanceComp-lianceRegulatoryInformation/Guidances/ucm64964.htm.
21. Wan, J.B., Lee, S.M., Wang, J.D., Wang, N., He, C.W., Wang, Y.T., Kang, J.X., Panax notoginseng reduces atherosclerotic lesions in ApoE-deficient mice and inhibits TNF-alpha-induced endothelial adhesion molecule expression and monocyte adhesion. J. Agric. Food Chem. 57 (2009), 6692–6697.
22. Wang, L., Yu, Y., Yang, J., Zhao, X., Li, Z., Dissecting Xuesaitong's mechanisms on preventing stroke based on the microarray and connectivity map. Mol. Biosyst. 11 (2015), 3033–3039.
23. Yang, X., Xiong, X., Wang, H., Wang, J., Protective effects of panax notoginseng saponins on cardiovascular diseases: a comprehensive overview of experimental studies. Evid. Based Complement. Altern. Med., 2014, 2014, 204840.
24. Yang, Y., The security of Xuesaitong capsule combined with aspirin in therapy of cerebral infarction patients. China Med. Eng. 22 (2014), 10–11.
25. Zeng, X.S., Zhou, X.S., Luo, F.C., Jia, J.J., Qi, L., Yang, Z.X., Zhang, W., Bai, J., Comparative analysis of the neuroprotective effects of ginsenosides Rg1 and Rb1 extracted from Panax notoginseng against cerebral ischemia. Can. J. Physiol. Pharmacol. 92 (2014), 102–108.